GERN

RYTELO quarterly net product revenue rose 27% year over year. Geron discontinued its Phase III trial in relapsed myelofibrosis.

Geron NASDAQ: GERN reported third-quarter net product revenue of $60.1 million for RYTELO, a 27% increase from $47.2 million a year earlier, as the company cited continued growth in prescribing, particularly among community practices.

Geron Corporation (GERN) Q3 2026 Earnings Call Transcript

Geron (GERN) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.03 per share a year ago.

FOSTER CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that six abstracts have been accepted for poster presentation at the 68th American Society of Hematology (ASH) Annual Meeting, to be held December 12-16, 2026, in New Orleans, LA.

Achieved $60.1 million in RYTELO ® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026

FOSTER CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat and be available for one-on-one meetings at the Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026 at 2:00 p.m.

Geron achieved FDA approval for RYTELO (imetelstat) in June 2024, targeting lower-risk myelodysplastic syndromes (LR-MDS). RYTELO is Geron's only advanced-stage asset, marking a pivotal milestone. GERN's recent pullback following its discontinuation of its IMpactMF trial has made it a compelling "Buy."

FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that it will release its third quarter 2026 financial results and business highlights before the market opens on Wednesday, November 4, 2026, via press release, which will be available on the Investors section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.

FOSTER CITY, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported that, effective October 16, 2026, it granted stock options to purchase an aggregate of 570,000 shares of common stock to three newly hired employees as an inducement material to such employees' acceptance of employment with Geron.